Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Abacavir
Drug ID BADD_D00008
Description Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.
Indications and Usage For the treatment of HIV-1 infection, in combination with other antiretroviral agents.
Marketing Status Prescription
ATC Code J05AF06
DrugBank ID DB01048
KEGG ID D07057
MeSH ID C106538
PubChem ID 441300
TTD Drug ID D0A4IJ
NDC Product Code 50268-049; 55111-920; 65862-073; 0121-0897; 72865-167; 0904-6874; 70518-1274; 31722-562; 31722-557; 69097-514; 64380-717
Synonyms abacavir | 1592U89 | abacavir sulfate | Ziagen | (1S,4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol | abacavir succinate
Chemical Information
Molecular Formula C14H18N6O
CAS Registry Number 136470-78-5
SMILES C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
HypersensitivityHLA class I histocompatibility antigen, B alpha chainP01889Not Available11888582; 15016610
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pulmonary embolism24.01.06.001; 22.06.02.0010.056669%Not Available
Purpura24.07.06.005; 23.06.01.004; 01.01.04.0030.018890%
Pyrexia08.05.02.0030.103893%
Rash23.03.13.0010.066114%Not Available
Renal disorder20.01.02.002--Not Available
Renal failure20.01.03.0050.004928%Not Available
Respiratory distress22.02.01.0120.028334%Not Available
Respiratory failure22.02.06.002; 14.01.04.003--
Rhabdomyolysis15.05.05.002--
Seizure17.12.03.001--
Skin disorder23.03.03.007--Not Available
Sleep disorder19.02.04.001--Not Available
Splenomegaly01.09.02.001--Not Available
Stevens-Johnson syndrome23.03.01.007; 11.07.01.005; 12.03.01.014; 10.01.03.020--
Stillbirth18.01.02.002; 08.04.01.0060.009855%Not Available
Stomatitis07.05.06.005--
Thrombocytopenia01.08.01.002--Not Available
Toxic epidermal necrolysis10.01.01.006; 23.03.01.008; 12.03.01.015; 11.07.01.006--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urticaria23.04.02.001; 10.01.06.0010.028334%
Vertigo04.04.01.003; 17.02.12.002--
Vomiting07.01.07.0030.047224%
Wheezing22.03.01.009--
Fat redistribution14.08.04.002--Not Available
Lipodystrophy acquired23.07.01.003; 14.08.04.008--Not Available
Deep vein thrombosis24.01.02.0030.075558%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Drug resistance08.06.01.0050.032030%Not Available
Urine output decreased13.13.03.0010.018890%
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages